LONDON, UNITED KINGDOM--(Marketwired - Dec. 4, 2013) -
Allerayde SAB Inc. (OTCQB:ASAB) President and CEO, Michael Rhodes, shares his insight into effective emergency treatment of potentially life-threatening allergic reactions along with strategic directions for the upcoming year in an exclusive interview on CEOinsiderTV.com
Allerayde SAB, Inc. announced today that Michael Rhodes, President and CEO of the Company has been featured in an in-depth interview on CEOinsiderTV.com.
The entire interview is available to watch for free at: http://ceoinsidertv.com/
In this exclusive interview Mr. Rhodes discusses the Company's innovative approach to solving a major drawback of existing emergency treatment of anaphylaxis related to allergies. He also shares future plans for the company. Specifically, he reveals:
- How strong demand for an innovative, low-cost high tech device for emergency treatment of severe allergic conditions will help fuel Allerayde's growth in the near future.
- The reason ASAB has significant advantage in realizing profits from distributing their new AAAPen® anaphylaxis treatment into non-traditional markets.
- Why Apple Computer's iPhone became an inspiration for the technology that will power new third-generation epinephrine auto-injectors from Allerayde.
- What role acquisitions play in Allerayde's growth strategy.
- And much more ...
Watch this informative interview video for free at: http://ceoinsidertv.com
About Allerayde SAB, Inc.:
Allerayde SAB, Inc. is engaged in the business of developing and manufacturing an innovative anaphylaxis pen product and other consumer health care products for allergy and eczema patients.
The Company's principal product is the AAAPen®. The AAAPen® is a new epinephrine/adrenaline pen for the emergency treatment of anaphylaxis, the severe allergic shock, which may be identified by various rapid onset symptoms following exposure to certain allergens - such as insect venoms, peanuts, seafood, latex, etc. - that have caused symptoms from different level reactions. When the first signs of anaphylaxis being experienced, the AAAPen® shall be used.
Allerayde is also engaged in developing and manufacturing products for the prevention and relief of allergy, asthma and eczema.
Allerayde SAB, Inc. trades on the Over the Counter Market with the ticker symbol ASAB. For more information about the company please visit our website at: www.alleraydesab.com
This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward‐looking public statements concerning its expected future operations, performance and other developments. Such forward‐looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such.
Forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, the Company's ability to develop operations, the Company's ability to consummate and complete an acquisition, the Company's access to future capital, the successful integration of acquired companies, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, sales and other factors that may be identified from time to time in the Company's public announcements.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.